Description

In this episode from the series “Key Decisions in HIV Care,” Daria Podlekareva, MD, PhD, and Mark S. Sulkowski, MD, discuss important considerations for ART use in patients with coinfections, including:

• DHHS testing and treatment recommendations for HBV in patients with HIV
• Data suggesting that tenofovir alone may not suppress HBV in all PWH
• Data from NA-ACCORD showing that incomplete HBV DNA suppression is associated with HCC in patients with HIV/HBV
• Data for the use of entecavir as an add-on therapy if an HIV ART regimen is not HBV active
• Data showing that lamivudine alone is associated with resistance in patients with HIV/HBV
• Discussion of HBV management in the setting of 2-drug regimens for HIV if the patient is coinfected
• Recommendations from the DHHS, EACS, and WHO to start ART as soon as possible in patients with TB/HIV coinfection
• Data from the SAPiT, ACTG A5221 STRIDE, and CAMELIA studies to show the benefits of early ART in patients with TB/HIV
• Recommendations from the EACS guidelines on what ART regimens are recommended with TB/HIV
• Drug-drug interaction considerations between ART and TB treatment
• Discussion of the prevention and management of TB-associated IRIS

Presenters:

Daria Podlekareva, MD, PhD
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark  

Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Chief, Infectious Disease
Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with slides:
https://bit.ly/3zHySMO

See the entire program at:
https://bit.ly/2TXTYWx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.